Bibliografia UJ CM

1/4
P. McEwan, A. Woehl, P[aweł] Kawalec, J. Lis, J. Gierczynski, J. Walczak.
Cost-utility of insulin glargine compared to NPH in type DMI from a public payer perspective in Poland.
Value in Health
2008 : Vol. 11, nr 6, s. A508, abstr. PDB40
ISPOR Eleventh Annual European Congress, Athens, Greece, November 8-11, 2008.
SZZ
SIF
2/4
P. McEwan, A. Woehl, P[aweł] Kawalec, J. Lis, J. Gierczynski, J. Walczak.
Cost-utility of insulin glargine compared to premix in type 2 from public payer perspective in Poland.
Value in Health
2008 : Vol. 11, nr 6, s. A509, abstr. PDB42
ISPOR Eleventh Annual European Congress, Athens, Greece, November 8-11, 2008.
SZZ
SIF
3/4
P. McEwan, A. Woehl, P[aweł] Kawalec, J. Lis, J. Gierczynski, J. Walczak.
Is insulin glargine a cost-effective option for treatment of patients naive to insulin treatment with type 2, baseline HBA 1C above 8% and age below 65 years in comparison to NPH and premix in Poland.
Value in Health
2008 : Vol. 11, nr 6, s. A507, abstr. PDB37
ISPOR Eleventh Annual European Congress, Athens, Greece, November 8-11, 2008.
SZZ
SIF
4/4
P. McEwan, A. Woehl, P[aweł] Kawalec, J. Lis, J. Gierczynski, J. Walczak.
Is insulin glargine a cost-effective option in treatment of patients with DMI with baseline HBAC above 8% in comparison to NPH and premix in Poland?
Value in Health
2008 : Vol. 11, nr 6, s. A508, abstr. PDB39
ISPOR Eleventh Annual European Congress, Athens, Greece, November 8-11, 2008.
SZZ
SIF
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ